LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Home・Akcijų sąrašas・Design Therapeutics Inc

Design Therapeutics Inc

Uždarymo kaina

10.7 1.42

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

10.16

Max

11.1

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-1.6M -18M
Pelnas, tenkantis vienai akcijai	-0.29
Darbuotojai	54
EBITDA	-1.5M -20M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+87.38% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-135M 665M
Ankstesnė atidarymo kaina	9.28
Ankstesnė uždarymo kaina	10.7

Design Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-06-09 23:49; UTC

Rinkos pokalbiai

Nikkei May Fall Following Tech Stock Declines on Wall Street -- Market Talk

2026-06-09 23:45; UTC

Įsigijimai, susijungimai, perėmimai

Correct: Sigma Healthcare: Has Engaged in Preliminary Discussions in Boots Sale Process

2026-06-09 23:44; UTC

Įsigijimai, susijungimai, perėmimai

Sigma Healthcare Says No Certainty That Any Transaction Will Eventuate

2026-06-09 23:44; UTC

Įsigijimai, susijungimai, perėmimai

Sigma Healthcare: Continuously Reviews Opportunities to Create Value For Shareholders

2026-06-09 23:43; UTC

Įsigijimai, susijungimai, perėmimai

Sigma Healthcare: Has Engaged in Preliminary Discussions to Sell Boots

2026-06-09 23:35; UTC

Rinkos pokalbiai

Oil Rises on Escalating Supply Disruption Concerns -- Market Talk

2026-06-09 22:06; UTC

Įsigijimai, susijungimai, perėmimai

Samsung: Element Has Expanded Rapidly Since 2022 Launch of AVITI

2026-06-09 22:05; UTC

Įsigijimai, susijungimai, perėmimai

Samsung: Element to Speed Commercialization of Gene-Sequencing Products

2026-06-09 22:05; UTC

Įsigijimai, susijungimai, perėmimai

Samsung: Additional Investment Makes It Largest Shareholder in Element

2026-06-09 22:05; UTC

Įsigijimai, susijungimai, perėmimai

Samsung Electronics Raises Stake in Element Biosciences With $175 Million Investment

2026-06-09 20:51; UTC

Uždarbis

Micron, Marvell, Super Micro, Coherent, Smucker, and More Stocks That Explain Today's Market -- Barrons.com

2026-06-09 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-06-09 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-06-09 20:09; UTC

Rinkos pokalbiai

Cryptocurrency Traders Look for Bitcoin Bottom -- Market Talk

2026-06-09 19:36; UTC

Rinkos pokalbiai

Cattle Climbs as Crude Oil Falls -- Market Talk

2026-06-09 19:32; UTC

Rinkos pokalbiai

Barclays Oil Price Outlook Contingent on Hormuz Reopening -- Market Talk

2026-06-09 19:25; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Slip in Rangebound Trade -- Market Talk

2026-06-09 19:00; UTC

Rinkos pokalbiai

Oil Settles Lower on Continued Hopes for Middle East Deal -- Market Talk

2026-06-09 18:52; UTC

Įsigijimai, susijungimai, perėmimai

Warner Bros. Stock Hits a Low. Its Paramount Merger Return Is Getting Buzz. -- Barrons.com

2026-06-09 18:47; UTC

Rinkos pokalbiai

No World Cup Inflation Seen So Far in Mexico -- Market Talk

2026-06-09 18:37; UTC

Rinkos pokalbiai

Canada's Cooling Trade With the U.S. -- Market Talk

2026-06-09 18:27; UTC

Rinkos pokalbiai

Precious Metals Lower as Trump Vows Military Response -- Market Talk

2026-06-09 17:35; UTC

Rinkos pokalbiai

Treasury Yields, Dollar Briefly Rise on Trump's Iran Retaliation Threat -- Market Talk

2026-06-09 17:30; UTC

Rinkos pokalbiai

Trump Post on Apache Helicopter Causes Brief Spike in Oil -- Market Talk

2026-06-09 16:34; UTC

Rinkos pokalbiai

Cryptocurrency Weakness Follows Selling in Equities -- Market Talk

2026-06-09 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-06-09 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-06-09 16:20; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Health Care Roundup: Market Talk

2026-06-09 15:28; UTC

Rinkos pokalbiai

Gold Futures Fall Further as Rate Fears Prevail -- Market Talk

2026-06-09 15:25; UTC

Rinkos pokalbiai

Oil Extends Losses, Falling More Than 3.5% -- Market Talk

Akcijų palyginimas

Kainos pokytis

Design Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

87.38% į viršų

12 mėnesių prognozė

Vidutinis 19.6 USD 87.38%

Aukščiausias 22 USD

Žemiausias 15 USD

Remiantis 6 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Design Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

6 ratings

Pirkti

Laikyti

Parduoti

Remiantis 6 analitikų, pateikusių Design Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Design Therapeutics Inc

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.